In a report issued on October 5, Douglas Miehm from RBC Capital reiterated a Hold rating on Bausch Health Companies Inc (NYSE: BHC), with a price target of $30. The company’s shares opened today at $26.85, close to its 52-week high of $28.45.
According to TipRanks.com, Miehm is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -8.2% and a 43.9% success rate. Miehm covers the Healthcare sector, focusing on stocks such as Novelion Therapeutics Inc, CRH Medical Corporation, and Shire.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bausch Health Companies Inc with a $26 average price target, implying a -3.2% downside from current levels. In a report issued on October 1, H.C. Wainwright also reiterated a Hold rating on the stock with a $25 price target.
Based on Bausch Health Companies Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $873 million. In comparison, last year the company had a net profit of $1.3 billion.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products.